Home | Print Page | Report Abuse | Sign In | Join
Clozapine-Induced Neutropenia: A Review of Lithium and Other Currently Available Options
Share |
Untitled Document

Clozapine-Induced Neutropenia: A Review of Lithium and Other Currently Available Options

By O. Greg Deardorff, Pharm.D., BCPP, Adjunct Clinical Assistant Professor, UMKC School of Pharmacy, Adjunct Clinical Faculty, St. Louis College of Pharmacy, Adjunct Clinical Faculty, MU School of Medicine, Clinical Manager, Fulton State Hospital, Fulton, Missouri; Kristin D. Ripperger, Pharm.D. Candidate, University of Missouri-Kansas City School of Pharmacy at MU, Columbia, Missouri. Reprinted with permission of the author.

Available options are limited for patients with neutropenia needing to be initiated or maintained on clozapine therapy. A common strategy that is often utilized in these patients is the use of lithium as augmentation to clozapine, which enables the health care provider a means of continuing or initiating clozapine therapy. Clozapine is the most effective antipsychotic based on data from the U.S. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)1 and the UK Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS)2, but comes with the associated risk of neutropenia. This article reviews unique aspects of using lithium as an augmentation to clozapine, as well as other strategies that can be considered for maintaining or initiating clozapine therapy in patients with neutropenia.

Many times our biggest challenge in using clozapine is finding a way to keep patients from developing neutropenia and keeping the absolute neutrophil counts (ANC) ?1500mm3 and white blood cell (WBC) counts ?3000/mm3. This is not an uncommon problem that health care providers encounter with patients on clozapine therapy. The conveyed frequency of agranulocytosis (<100 cells/mm3) and granulocytopenia (< 1500 cells/µL) is 0.6% and 28%, respectively.3 The Clozaril Patient Monitoring Services revealed 0.4% of patients had pre-treatment white blood cell counts too low to allow initiation of clozapine. Of these patients, 75% were of African or African-Caribbean descent,4 likely due to the increased leukocyte marginalization that has been shown to be more prominent in these populations. Of all neutrophils in the body, 90% reside in the bone marrow and the remainder circulates freely in the blood or deposits next to vessel walls (marginalization). The addition of lithium has been shown to increase neutrophil counts by 2000/mm3, which is in part through demarginalization of leukocytes.5 This increase is not dose related but may require a lithium level of 0.4-1.1 mEq/L depending upon each individual patient.6 Since leukocyte marginalization appears to be more consistent in patients of African or African-Caribbean descent, it stands to reason that demarginalization of leukocytes caused by lithium may have more prominent effects in these populations.

A commonly asked question regarding lithium-induced leukocytosis is if this desired side effect increases the body’s ability to fight off infection. To answer this question, we need to understand how lithium is proposed to cause leukocytosis. Lithium not only works by demarginalization or redistribution of granulocytes in the marrow reserve, but also by upregulation of granulopoiesis-stimulating factors, in addition to hypercortisolaemia.6 Hematological parameters gradually improve during the first week of lithium administration, consistent with the time frame of patients administered granulocyte–macrophage CSF (GMCSF) or granulocyte colony-stimulating factors (G-CSF)3, which are known to boost the immune system to aid in fighting off infections. Lithium opposes prostaglandin E2, which has been demonstrated to have effects on bacteria, parasites, and even pathogenic fungi.7 Prodigious production of prostaglandin E2 causes stimulation of microorganisms and suppression of humoral and cell-mediated immunity.7 Immunostimulation is nonspecific and may be relevant to different types of infections. Lithium has been shown to inhibit the replication of type 1 and 2 herpes virus in cell cultures, in addition to reportedly inducing remission of viral infections such as sinusitis, sinobronchitis, frequent colds, sore throats, cold sores and genital herpes.8-13 A 29-year-old woman with a long history of recurrent skin infections was shown to have diminished polymorphonuclear neutrophil cAMP levels and restored normal chemotactic responsiveness when administered lithium and relapsed when lithium was discontinued.7 In contrast, other articles have shown lithium-induced neutrophils in vitro showing less bactericidal properties than non-lithium induced neutrophils.14

Another strategy for obtaining appropriate WBC and ANC levels that will enable clozapine initiation and/or continuation would be to obtain blood samples later in the day. A recently published study compared the same set of patients having early morning blood draws to blood draws taken later in the day (mean sampling time — pre/post was 5 hours 24 minutes).15 A difference in pre/post time change in WBC values were shown to be marginally significant (mean increase=667/mm3, p=.07), with a significant difference (mean increase=1,130/mm3, p=.003) between the pre/post time change in ANC values. ANC values were impacted to a greater extent by the time change than WBC values in this sample.

A strategy implemented at our facility exploiting this diurnal variation in neutrophil function, which assists in initiating and continuing clozapine therapy, is utilizing a point-of-care (POC) lab device, which can be purchased for around $14,000. This device allows a complete blood count (CBC) plus 3-part differential to be completed by finger stick requiring 5-6 drops of blood instead of weekly blood draws that both patients and health care providers find to be a major barrier to clozapine therapy. Many factors, including patient irritation and violent behavior when having their blood drawn on a consistent basis, have been noted by our physicians as the biggest obstacle in utilizing clozapine. Another obstacle is contracting out with a clinical laboratory, which typically means patients will receive early morning blood draws. A point-of-care lab device not only allows labs to be drawn at a later time of the day, but also allow patients a less invasive means to acquire lab draws on a consistent basis.

Changing the time at which blood draws are taken during the day may allow for clozapine continuation by limiting the risk of pseudoneutropenia; however it remains the clinician’s responsibility to discern between benign or malignant neutropenia.15 It is recommended that patients with WBC values trending down or below the predefined criteria have labs redrawn several hours after the morning lab, prior to discontinuing clozapine therapy.15 If the addition of lithium is used as augmentation to clozapine therapy for the prevention or correction of neutropenia, it still remains a matter of clinical judgment and should be based upon each individual patient. According to the available literature, lithium appears to not only help prevent patients from developing neutropenia, but is also a relatively safe medication if monitored appropriately.

1 McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163:600–10.
2 Lewis SW, Barnes TRE, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006;32:715–23.
3 P. Blier, S. Slater, and T. Measham, M Koch and G. Wiviott. Lithium and clozapine-induced neutropenia/agranulocytosis. International Clinical Psychopharmacology 1998; 13:137-140.
4 Atkin K, Kendall F, Gould D, et al. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Brit J Psychiatry 1996;169:483-488.
5 Small JG, Klapper MH, Malloy FW, et al. Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. J Clin Psychopharmacol 2002;23:223-228
6 David Esposito, Frederic Rouillon and Frederic Limosin. Continuing clozapine treatment despite neutropenia. Eur J Clin Pharmacol 2005;60:759–764.
7 Julian Lieb. Lithium and antidepressants: Stimulating immune function and preventing and reversing infection. Medical Hypotheses 2007;69:8–11.
8 Lieb J. Remission of herpes virus infection and immunopotentiation with lithium carbonate: inhibition of prostaglandin E1 synthesis by lithium may explain its antiviral, immunopotentiating, and antimanic properties. Biol Psychiat 1981:695–8.
9 Hansell N. Manic illness presenting with physical symptoms.Am J Psychiatry 1990;147(11):1575.
10 Amsterdam J, Maislin G, Rybakowski J. A possible antiviral action of lithium carbonate in herpes simplex virus infections. Biol Psychiat 1990;27:447–53.
11 Shenkman L, Borkowsky W, Shopsin B. Lithium as an immunologic adjuvant. Med hypothesis 1980;6:1–6.
12 Skinner G, Hartley C, Buchan A, Harper L, Gallimore P. The effect of lithium chloride on the replication of herpes simplex virus. Med Microbiol Immunol 1980;168:139–48.
13 Weetman A, McGregor A, Lazarua J, Smith BR, Hall R. The enhancement of immunoglobulin synthesis by human lymphocytes with lithium. Clin Immunol 1982;22:400–7.
14 Friedenberg, W., Marx, J. (1980) The effect of lithium carbonate on lymphocyte, granulocyte and platelet function. Cancer 45, 91–97.
15 McKee JR, Wall T, Owens J. Impact of complete blood count sampling time change on white blood cell and absolute neutrophil count values in clozapine recipients. Clin Schizophr Relat Psychoses 2011;26-32.

Editor’s Note: This article is reprinted with permission. Deardorff GO, Ripperger KD. Clozapine-induced neutropenia: A review of lithium and other currently available options. Ment Health Clin. 2012;2(1):13. Available at: http://cpnp.org/resource/mhc/2012/07/clozapine-induced-neutropenia-review-lithium-and-other-currently-available.

    Minnesota Pharmacists Association

    1000 Westgate Drive, Suite 252, St. Paul, MN 55114 | Phone: 651.697.1771 Fax: 651.290.2266 Email: info@mpha.org
    © 2017 MPhA. All Rights Reserved.